Nuclein has closed a $14 million Series B funding round, led by Trinity Private Equity Group (TPEG), a Southlake, Texas-based private equity firm.

Nuclein, LLC was founded in 2017 by long-time Austin biotechnology entrepreneurs Alan Blake and Dr. Richard Crockett. The company's vision is to enable simple, affordable, rapid, and accurate disease testing for everyone.